Advance in Antibody Based Cancer Therapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2988
Special Issue Editor
Interests: cancer therapy; drug delivery; immunoconjugates; immune targeting; plant toxins
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibody-based cancer therapeutics have achieved unprecedented success for the treatment of various diseases, including cancer, immune disorders, and infectious diseases.
Over the past few decades, a huge number of studies have established the efficacy of monoclonal antibodies (mAbs) in targeted cancer therapy. The efficacy of antibody-based cancer therapy depends on specific characteristics of the surface antigen recognized by the mAb by the target cells. The selected antigens should have: easy accessibility, high expression on targeted malignant cells, and low or no expression on healthy non-target cells. The main cytotoxic mechanisms activated by the complex mAb-antigen are complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Furthermore, some antibodies can directly kill the target cell by activating apoptosis. However, antibody cytotoxicity is often limited due to resistance to CDC and ADCC or to the selection of tumor clones resistant to the antibody-triggered apoptosis. Several strategies have been adopted to overcome these obstacles to improve antibodies efficacy: for example, antibodies can be used in combination with standard chemotherapy, can be administered to patients with high-response cancer subtypes, antibodies can also be linked to pharmacologically active molecules, combining the specificity of the antibody with the therapeutic effects of these molecules.
This Special Issue will cover all aspects of the mechanism and efficacy of antibody-based therapeutics in cancer treatment either as single agents or as combined therapeutics. Original papers and review articles are welcomed.
Dr. Letizia Polito
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody
- biomedicines
- biopharmaceutical products
- cancer therapy
- drug delivery
- immunoconjugates
- immunotoxins
- immunotherapy
- immunotargeting
- nanodelivery
